Is erdafitinib included in medical insurance when it is launched in China?

Erdafitinib is a targeted therapy drug used to treat a specific type of advanced or metastatic urothelial carcinoma (urothelial carcinoma). Urothelial carcinoma is a malignant tumor originating from the urinary system, including the bladder, renal pelvis, and ureters. For some patients whose disease has progressed after chemotherapy, erdafitinib provides a new treatment option.

Erdafitinib is not currently available on the domestic market, so patients cannot directly purchase it domestically and can only obtain it through overseas channels. Among them, the original drugs are mainly Hong Kong, China version, which are expensive, up to more than 20,000 yuan, and need to be purchased through pharmacies in Hong Kong, China. Overseas generic drugs are more affordable, mainly including generic versions of Yaopin International from Laos and Bangladesh, with prices ranging from a few hundred yuan to more than 2,000 yuan. It is worth mentioning that the ingredients of these generic drugs and the original drugs are roughly the same.

Erdafitinib belongs to a class of drugs called multikinase inhibitors, which work by inhibiting multiple key kinases in tumor cells. The most important target is FGFR (fibroblast growth factor receptor) kinase. FGFR has been found to be abnormally active in many cancers, promoting tumor growth and spread. By inhibiting FGFR, erdafitinib can interfere with the proliferation and survival of tumor cells, thereby inhibiting cancer progression.

Clinical trials have shown that erdafitinib shows good efficacy in the treatment of advanced urothelial cancer. Some studies have shown that some patients treated with erdafitinib have significant tumor shrinkage or disease stabilization. This is an important advance for patients whose disease has worsened despite multiple treatments.

However, like all medicines, erdafitinib may cause some side effects. Some common side effects include fatigue, nausea, vomiting, diarrhea, rash, etc. In addition, due to the mechanism of action of erdafitinib, it may cause some more serious adverse reactions, such as hypertension, visual impairment, abnormal liver function, etc. Therefore, before using erdafitinib, doctors will evaluate the patient's overall health and closely monitor the patient's response.